Laurea Magistrale in Medicina e Chirurgia - sede di Torino

Insegnamenti

• Cancer Cellular Biology
  Molecular Medicine PhD Program
• I. Struttura e morfologia del corpo umano - Canale B (MSL0259)
  Corso di laurea in Infermieristica - sede Orbassano Polo Medicina Orbassano e Candiolo
• Istologia can.B (MSL0259C)
  Corso di laurea in Infermieristica - sede Orbassano Polo Medicina Orbassano e Candiolo
• Istologia ed embriologia (canale B) (SME0716)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• TIROCINIO di BIOLOGIA CELLULARE DEL CANCRO (SME0910)
  Corso di Laurea Magistrale in Biotecnologie Mediche - Classe LM-9

Temi di ricerca

CURRENT RESEARCH PROJECTS 

-Since 2018 she has been working as Principal Investigator in the Lab. of Cancer Molecular Biology of Candiolo Cancer Institute, FPO-IRCCS, where she has been coordinating a research group to study cell-autonomous and non-cell autonomous mechanisms of resistance (Apicella M, 2018, CELL METABOLISM (Corso S. Last co-author); Ughetto et al, (Corso S. Last co-author);  2021 Rizzolio et al, 2022, J EXP CLIN CANCER RES (Corso S. Last Author).

-In collaboration with Prof. Giordano, she has recently generated a molecularly annotated platform of gastric Patient-Derived Xenografts (at present, the widest gastric PDX platform generated in an academic institution). This platform allowed the identification of several new molecular targets in gastric cancer: S. Corso et al (2019) A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. CANCER RESEARCH (First and Corresponding author). Corso S, et al. (2018) Rituximab treatment prevents lymphoma onset in gastric cancer Patient-Derived-Xenografts. NEOPLASIA (First author); Apicella M. et al. (2017), ‘Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort’ ONCOGENE (Co-Last and Corresponding author). Corso et al. (2021), Optimized EGFR blockade strategies in EGFR addicted gastroesophageal cancer, CLINICAL CANCER RESEARCH (First and Corresponding author).; Pietrantonio et al, (2022) ‘HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial’, CLINICAL CANCER RESEARCH; Petrelli et al, (2023), ‘BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors’, CANCER RESEARCH (Co-Corresponding author): Piliga et al (2024), ‘Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models’, GASTRIC CANCER; Conticelli et al (2025), ‘AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer, CANCER RESEARCH ’ (Co-Corresponding author).

Attività in agenda

Consulta la mia agenda

Organi

• Department Council - Department of Oncology

• Commissione per la Ricerca - Dipartimento di Oncologia

• Collegio Docenti

Ricevimento studenti